ClearOne is trading 5.7% down at $6.22 in pre-market, extending sharp volatility following its recently announced merger with Cortigent, a Vivani Medical subsidiary.
- The deal includes a planned $10–$15 million S-1 capital raise, which will leave Vivani owning roughly 59–68% of the combined company.
- Existing shareholders face significant dilution from the transaction, leading traders to reassess the stock's risk profile after last week’s outsized gains.